Advertisement

Annals of Surgical Oncology

, Volume 22, Issue 8, pp 2633–2639 | Cite as

Additional Primary Malignancies in Patients with Gastrointestinal Stromal Tumor (GIST): A Clinicopathologic Study of 260 Patients with Molecular Analysis and Review of the Literature

  • Jaclyn Frances Hechtman
  • Ronald DeMatteo
  • Khedoudja Nafa
  • Ping Chi
  • Maria E. Arcila
  • Snjezana Dogan
  • Alifya Oultache
  • Wen Chen
  • Meera Hameed
Bone and Soft Tissue Sarcomas

Abstract

Background

The incidence of other primary neoplasms in gastrointestinal stromal tumor (GIST) patients is relatively high. Our aim was to better characterize the clinicopathologic and molecular relationships in a cohort of GIST patients.

Methods

All GIST patients with tumor samples sent for molecular testing were identified via electronic medical records. Clinicopathologic characteristics of GIST and additional primary malignancies were analyzed.

Results

Of 260 patients, 50 (19 %) had at least one additional primary malignancy. In 33 patients, separate primary neoplasms predated their GIST diagnosis and most commonly included: prostate (n = 9), breast (n = 8), and hematologic (n = 5). Renal (n = 4) and hematologic (n = 3) malignancies were the most frequent cancers identified after GIST diagnosis. The majority (8 of 12, 66 %) of malignancies diagnosed after GIST were found incidentally. Patients who developed other malignancies after GIST more often had KIT exon 11 mutations (100 vs. 66 %, P = 0.01). In comparison to patients with only GIST, patients with a second primary neoplasm of any chronology had GISTs with increased mitotic rate (≥5 per 50 high-power fields) (P = 0.0006). Literature review revealed colorectal cancer, gastric, prostate, renal, leukemia, and desmoid-type fibromatosis as the most common secondary neoplasms.

Conclusions

Nineteen percent of GIST patients develop other malignancies. This is the first report to describe a relationship between additional primary malignancy and both mutation and mitotic rate of GIST. Although the basis of these relationships remains to be investigated, caution in the clinical management of GIST patients with additional lesions is warranted.

Keywords

Renal Cell Carcinoma Imatinib Chronic Lymphocytic Leukemia Papillary Thyroid Carcinoma Seminoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

The authors declare no conflict of interest.

Supplementary material

10434_2014_4332_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 18 kb)

References

  1. 1.
    Ducimetière F, Lurkin A, Ranchère-Vince D, et al. Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. PLoS One. 2011;6:e20294.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Mazzola P, Spitale A, Banfi S, et al. Epidemiology and molecular biology of gastrointestinal stromal tumors (GISTs): a population-based study in the South of Switzerland, 1999–2005. Histol Histopathol. 2008;23:1379–86.PubMedGoogle Scholar
  3. 3.
    Wozniak A, Rutkowski P, Piskorz A, et al. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Ann Oncol. 2012;23:353–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Corless CL, Ballman KV, Antonescu CR, et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol. (in press).Google Scholar
  5. 5.
    Robson ME, Glogowski E, Sommer G, et al. Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Res. 2004;10:1250–4.PubMedCrossRefGoogle Scholar
  6. 6.
    DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–8.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Agaimy A, Wünsch PH, Sobin LH, Lasota J, Miettinen M. Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol. 2006;23:120–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466–78.PubMedGoogle Scholar
  9. 9.
    National Cancer Institute. Probability of developing cancer. http://seer.cancer.gov/faststats/selections.php. Accessed 11 Nov 2014.
  10. 10.
    Pandurengan RK, Dumont AG, Araujo DM, et al. Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol. 2010;21:2107–11.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Au WY, Ho KM, Shek TW. Papillary renal cell carcinoma and gastrointestinal stromal tumor: a unique association. Ann Oncol. 2004;15:843–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Dumont AG, Rink L, Godwin AK, et al. A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Ann Oncol. 2012;23:1335–40.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Gonçalves R, Linhares E, Albagli R, et al. Occurrence of other tumors in patients with GIST. Surg Oncol. 2010;19:e140–3.PubMedCrossRefGoogle Scholar
  14. 14.
    Miettinen M, Kraszewska E, Sobin LH, Lasota J. A nonrandom association between gastrointestinal stromal tumors and myeloid leukemia. Cancer. 2008;112:645–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Lin M, Lin JX, Huang CM, et al. Prognostic analysis of gastric gastrointestinal stromal tumor with synchronous gastric cancer. World J Surg Oncol. 2014;12:25.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Froelich JJ, Schneller FR, Zahn RK. The influence of radiation and chemotherapy-related DNA strand breaks on carcinogenesis: an evaluation. Clin Chem Lab Med. 1999;37:403–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Bhatia S. Therapy-related myelodysplasia and acute myeloid leukemia. Semin Oncol. 2013;40:666–75.PubMedCrossRefGoogle Scholar
  18. 18.
    Kanda T. Criminal or bystander: imatinib and second primary malignancy in GIST patients. Chin J Cancer Res. 2013;25:490–2.PubMedCentralPubMedGoogle Scholar
  19. 19.
    Novartis Pharmaceuticals Corporation. Highlights of prescribing information. October 2013. http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf. Accessed 10 March 2014.
  20. 20.
    Horstmann M, Hennenlotter J, Geiger LM, et al. Evaluation of the KIT/stem cell factor axis in renal tumours. Anticancer Res. 2012;32:4339–45.PubMedGoogle Scholar
  21. 21.
    Kulaylat MN, Karakousis CP, Keaney CM, et al. Desmoid tumour: a pleomorphic lesion. Eur J Surg Oncol. 1999;25:487–97.PubMedCrossRefGoogle Scholar
  22. 22.
    Coffey J, Linger R, Pugh J, et al. Somatic KIT mutations occur predominantly in seminoma germ cell tumors and are not predictive of bilateral disease: report of 220 tumors and review of literature. Genes Chromosom Cancer. 2008;47:34–42.PubMedCrossRefGoogle Scholar
  23. 23.
    Torres-Cabala CA, Wang WL, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol. 2009;22:1446–56.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Rusakiewicz S, Semeraro M, Sarabi M, et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 2013;73:3499–510.PubMedCrossRefGoogle Scholar
  25. 25.
    Hechtman JF, Donovan MJ, McBride RB, et al. Intratumoral CD8+ cells are strongly and inversely correlated with mitotic index index and estimated recurrence-free survival in treatment-naïve gastric GISTs (abstract). Lab Invest. 2013;93:153A–4A.Google Scholar
  26. 26.
    Balachandran VP, Cavnar MJ, Zeng S, et al. Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumors through the inhibition of Ido. Nat Med. 2011;17:1094–100.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2015

Authors and Affiliations

  • Jaclyn Frances Hechtman
    • 1
  • Ronald DeMatteo
    • 2
  • Khedoudja Nafa
    • 1
  • Ping Chi
    • 3
  • Maria E. Arcila
    • 1
  • Snjezana Dogan
    • 1
  • Alifya Oultache
    • 1
  • Wen Chen
    • 4
  • Meera Hameed
    • 1
  1. 1.Department of PathologyMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Department of SurgeryMemorial Sloan Kettering Cancer CenterNew YorkUSA
  3. 3.Department of MedicineMemorial Sloan Kettering Cancer CenterNew YorkUSA
  4. 4.Department of PathologyVeterans’ Affairs HospitalWashingtonUSA

Personalised recommendations